A Study to Determine if There is a Possible Association Between NAION and Phosphodiesterase Type 5 (PDE5) Inhibitors
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01131104|
Recruitment Status : Completed
First Posted : May 26, 2010
Results First Posted : April 5, 2018
Last Update Posted : April 5, 2018
|Study Design||Observational Model: Case-Crossover; Time Perspective: Prospective|
Nonarteritic Anterior Ischemic Optic Neuropathy
Drug: PDE5 Inhibitors
Study Set were enrolled participants who met inclusion/exclusion criteria and physician-diagnosed Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)known date of onset.
Adjudication-Confirmed NAION Set were confirmed participants (by adjudication committee) with inclusion/exclusion criteria and physician-diagnosed NAION known date of onset.